Aficamten Phase 3 SEQUOIA-HCM meets primary endpoint: pVO2 improved 1.8 vs 0.0 mL/kg/min (p=0.000002)

CYTOKINETICS INC

All 10 prespecified secondary endpoints met, including KCCQ-CSS (+7 points, p<0.0001) and NYHA class improvement (34%, p<0.0001).
Treatment reduced days eligible for septal reduction therapy by 78 days vs placebo (p<0.0001).
No treatment interruptions due to low LVEF; serious adverse events 5.6% aficamten vs 9.3% placebo.
Results presented at ESC Heart Failure 2024 and published in New England Journal of Medicine.
Composite responder endpoint achieved by 42% aficamten vs 14% placebo (p<0.0001).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.